全文获取类型
收费全文 | 219725篇 |
免费 | 3582篇 |
国内免费 | 108篇 |
专业分类
耳鼻咽喉 | 1803篇 |
儿科学 | 8376篇 |
妇产科学 | 3843篇 |
基础医学 | 22427篇 |
口腔科学 | 3125篇 |
临床医学 | 15303篇 |
内科学 | 41786篇 |
皮肤病学 | 2276篇 |
神经病学 | 20233篇 |
特种医学 | 9872篇 |
外科学 | 34488篇 |
综合类 | 2560篇 |
一般理论 | 16篇 |
预防医学 | 21934篇 |
眼科学 | 3953篇 |
药学 | 12096篇 |
中国医学 | 859篇 |
肿瘤学 | 18465篇 |
出版年
2024年 | 35篇 |
2023年 | 395篇 |
2022年 | 436篇 |
2021年 | 1496篇 |
2020年 | 728篇 |
2019年 | 1537篇 |
2018年 | 23836篇 |
2017年 | 18437篇 |
2016年 | 20451篇 |
2015年 | 1939篇 |
2014年 | 2117篇 |
2013年 | 2856篇 |
2012年 | 10434篇 |
2011年 | 24704篇 |
2010年 | 20508篇 |
2009年 | 12584篇 |
2008年 | 22335篇 |
2007年 | 24503篇 |
2006年 | 3154篇 |
2005年 | 4856篇 |
2004年 | 5798篇 |
2003年 | 6695篇 |
2002年 | 4555篇 |
2001年 | 1710篇 |
2000年 | 2241篇 |
1999年 | 1178篇 |
1998年 | 464篇 |
1997年 | 355篇 |
1996年 | 242篇 |
1995年 | 237篇 |
1994年 | 196篇 |
1993年 | 158篇 |
1992年 | 181篇 |
1991年 | 207篇 |
1990年 | 225篇 |
1989年 | 179篇 |
1988年 | 149篇 |
1987年 | 110篇 |
1986年 | 89篇 |
1985年 | 100篇 |
1984年 | 91篇 |
1983年 | 69篇 |
1982年 | 66篇 |
1981年 | 33篇 |
1980年 | 75篇 |
1978年 | 37篇 |
1938年 | 61篇 |
1934年 | 30篇 |
1932年 | 58篇 |
1930年 | 47篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
Estefany I. Medina-Reyes Carolina Rodríguez-Ibarra Daniel Díaz-Urbina Alejandro Déciga-Alcaraz Normal L. Delgado-Buenrostro Yolanda I. Chirino José Pedraza-Chaverri 《Journal of applied toxicology : JAT》2022,42(8):1411-1419
Food-grade titanium dioxide (E171) is widely used as a food additive, and it is known that after oral consumption, E171 is translocated into the bloodstream reaching the highest titanium level at 6 h. E171 is accumulated in some organs triggering toxicity, but the effects on the blood parameters after oral consumption have been less studied. Recently, evidence shows that oral exposure to E171 induces behavioral signs of anxiety and depression. The relation between blood alterations and psychiatric disorders has been previously demonstrated. However, the oral exposure to E171 effects on alterations in blood parameters and effects linked to alterations in animal behavior has not been explored. In this short communication, we aimed to investigate the effects of E171 on specific blood parameters (hematocrit, hemoglobin, number of erythrocytes, and leukocytes) and anxiety and compulsive-like behavior in males and females orally exposed to ~5 mg/kg for 4 weeks. The results showed that E171 decreased hematocrit and hemoglobin in male but not in female mice while leukocyte and erythrocyte count remained unaltered. Oral consumption of E171 decreased the levels of anxiety-like behavior in females but not in male mice, while compulsive-like behavior was increased in both male and female mice. 相似文献
32.
33.
Kelly H. M. Cooijmans Roseriet Beijers Bonnie E. Brett Carolina de Weerth 《Maternal & child nutrition》2022,18(1):e13241
This randomized controlled trial evaluated the effect of a 5-week daily skin-to-skin contact (SSC) intervention between mothers and their full-term infants, compared with care-as-usual, on exclusive and continued breastfeeding duration during the first post-natal year. Healthy pregnant women (n = 116) from a community sample were enrolled and randomly allocated to the SSC or care-as-usual condition. SSC mothers were requested to provide one daily hour of SSC for the first five post-natal weeks. Twelve months post-partum, mothers indicated the number of exclusive and continued breastfeeding months. Multiple regression analyses were conducted using intention-to-treat, per-protocol and exploratory dose–response frameworks. In intention-to-treat analyses, exclusive and continued breastfeeding duration was not different between groups (exclusive: 3.61 ± 1.99 vs. 3.16 ± 1.77 months; adjusted mean difference 0.28, 95% confidence interval [CI] ?0.33 to 0.89; p = 0.36; continued: 7.98 ± 4.20 vs. 6.75 ± 4.06 months; adjusted mean difference 0.81, 95% CI ?0.46 to 2.08; p = 0.21). In per-protocol analyses, exclusive and continued breastfeeding duration was longer for SSC than care-as-usual dyads (exclusive: 4.89 ± 1.26 vs. 3.25 ± 1.80 months; adjusted mean difference 1.28, 95% CI 0.31–2.24; p = 0.01; continued: 10.81 ± 1.97 vs. 6.98 ± 4.08 months; adjusted mean difference 2.33, 95% CI 0.13–4.54; p = 0.04). Exploratory dose–response effects indicated that more SSC hours predicted longer exclusive and continued breastfeeding duration. This study demonstrates that for the total group, the 5-week daily SSC intervention did not extend exclusive and continued breastfeeding duration. However, for mothers performing a regular daily hour of SSC, this simple and accessible intervention may extend exclusive and continued breastfeeding duration by months. Future studies are required to confirm these promising findings. Trial registration: Netherlands Trial Register (NTR5697). 相似文献
34.
Martín-Nares Eduardo Zuñiga-Tamayo Diego Hinojosa-Azaola Andrea 《Clinical rheumatology》2019,38(1):97-106
Clinical Rheumatology - We aimed to estimate the frequency of overlap of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with systemic autoimmune diseases. Retrospective... 相似文献
35.
36.
37.
A. Hochsprung S. Escudero-Uribe A.J. Ibáñez-Vera G. Izquierdo-Ayuso 《Neurología (Barcelona, Spain)》2021,36(6):433-439
IntroductionPain is highly prevalent in patients with multiple sclerosis (MS); it is chronic in 50% of cases and is classified as nociceptive, neuropathic, or mixed-type. Pain affects quality of life, sleep, and the activities of daily living. Electrotherapy is an interesting alternative or complementary treatment in the management of pain in MS, with new innovations constantly appearing.Material and methodsThis study evaluates the effectiveness of treatment with monopolar dielectric transmission of pulsed electromagnetic fields (PEMF) for pain associated with MS. We performed a randomised, placebo-controlled clinical trial including 24 patients, who were assessed with the Brief Pain Inventory, the Multiple Sclerosis International Quality of Life questionnaire, the Beck Depression Inventory, and the Modified Fatigue Impact Scale.ResultsStatistically significant improvements were observed in maximum and mean pain scores, as well as in the impact of pain on work, personal relationships, and sleep and rest. Not significant differences were found between the treatment and placebo groups.ConclusionsTreatment with PEMF may be effective in reducing pain in patients with MS, although further research is necessary to confirm its effectiveness over placebo and to differentiate which type of pain may be more susceptible to this treatment. 相似文献
38.
39.
40.
Ana M. Gómez Angelica Imitola Diana Henao Maira García-Jaramillo Marga Giménez Clara Viñals Bruno Grassi Mariana Torres Isabella Zuluaga Oscar Mauricio Muñoz Martin Rondón Fabián León-Vargas Ignacio Conget 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(1):267-272
Background and aimsDespite using sensor-augmented pump therapy (SAPT) with predictive low-glucose management (PLGM), hypoglycemia is still an issue in patients with type 1 Diabetes (T1D). Our aim was to determine factors associated with clinically significant hypoglycemia (<54 mg/dl) in persons with T1D treated with PLGM-SAPT.Methodology: This is a multicentric prospective real-life study performed in Colombia, Chile and Spain. Patients with T1D treated with PLGM-SAPT, using sensor ≥70% of time, were included. Data regarding pump and sensor use patterns and carbohydrate intake from 28 consecutive days were collected. A bivariate and multivariate Poisson regression analysis was carried out, to evaluate the association between the number of events of <54 mg/dl with the clinical variables and patterns of sensor and pump use.Results188 subjects were included (41 ± 13.8 years-old, 23 ± 12 years disease duration, A1c 7.2% ± 0.9). The median of events <54 mg/dl was four events/patient/month (IQR 1–10), 77% of these events occurred during day time. Multivariate analysis showed that the number of events of hypoglycemia were higher in patients with previous severe hypoglycemia (IRR1.38; 95% CI 1.19–1.61; p < 0.001), high glycemic variability defined as Coefficient of Variation (CV%) > 36% (IRR 2.09; 95%CI 1.79–2.45; p < 0.001) and hypoglycemia unawareness. A protector effect was identified for adequate sensor calibration (IRR 0.77; 95%CI 0.66–0.90; p:0.001), and the use of bolus wizard >60% (IRR 0.74; 95%CI 0.58–0.95; p:0.017).ConclusionIn spite of using advanced SAPT, clinically significant hypoglycemia is still a non-negligible risk. Only the identification and intervention of modifiable factors could help to prevent and reduce hypoglycemia in clinical practice. 相似文献